Meta­vant makes a de­but: Vivek Ra­maswamy launch­es biotech #7 and builds a di­a­betes pipeline with Lig­and deal

Just be­cause David Hung re­cent­ly left one of Vivek Ra­maswamy’s Vant sub­sidiaries short­ly af­ter its lead ther­a­py im­plod­ed in a failed piv­otal study for Alzheimer’s is no rea­son for the multi­bil­lion-dol­lar out­fit to stop do­ing deals and set­ting up new biotechs.

Ra­maswamy is fork­ing over $20 mil­lion in cash and promis­ing $513.8 mil­lion in mile­stones to grab a new di­a­betes drug from Lig­and with Phase II da­ta ready to roll. Lig­and spelled out the terms of the deal in an SEC fil­ing to­day as Roivant dropped the news that it is now ramp­ing up biotech #7: Meta­vant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.